Skip to Content

'
Muzaffar H. Qazilbash, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

1. Stem Cell Transplantation for Multiple Myeloma 

2. Cancer Vaccines

3. # 2 Immunotherapy

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: Unit 423
Houston, TX 77030
Room Number: FC5.2006
Email: mqazilba@mdanderson.org

Education & Training

Degree-Granting Education

1987 University of Karachi, School of Medicine, Karachi, Pakistan, Pakistan, MD, MD

Postgraduate Training

7/1992-6/1995 Fellow, Hematology and Oncology, Dr. C. E. Dunbar, National Heart Lung and Blood Institute and National Cancer Institute National Institutes of Health, Bethesda, MD
7/1991-6/1992 Clinical Residency, The University of Connecticut, Farmington, CT
7/1989-6/1991 PGY-Y and 2, Internal Medicine Dr. H. V. Barnes, Wright State University, Dayton, OH

Board Certifications

2018 American Board of Internal Medicine (Medical Oncology)
2016 American Board of Internal Medicine ( Hematology)
2/2014 American Board of Internal Medicine, Board Certificate

Experience/Service

Administrative Appointments/Responsibilities

Co-Director, Stem Cell Transplantation Fellowship Program, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2008-present

Institutional Committee Activities

Co-Director, Stem Cell Transplantation Fellowship Program, 9/2008-present
Associate Director, Hematology/Oncology Fellowship Program, 8/2008-1/2010
Member, Faculty Senate, 9/2007-8/2010
Member, Institutional Research Grants (IRG) Committee, 9/2006-2009

Professional Memberships

American Association for Advancement of Sciences
Member, 2006-present
American Society of Blood and Marrow Transplantation
Member, 2006-present
American Society of Clinical Oncology
Member, 2006-present
American Society of Hematology
Member, 2006-present
ASBMT Committee on Research Priorities
Member, 2013-present
Frontiers in Oncology (Hematology Oncology)
Review Editor, 1/2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Qazilbash MH, Walsh CE, Russell SM, Noguchi M, Mann MM, Leonard WJ, Liu JM. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. J Hematother 4:91-8, 4/1995. PMID: 7633846.
2. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type. Gene Ther 4:675-82, 7/1997. PMID: 9282168.
3. Qazilbash MH, Liu JM, Vlachos A, Fruchtman S, Messner H, Zipursky A, Alter BP, Young NS. A new syndrome of familial aplastic anemia and chronic liver disease. Acta Haematol 97:164-7, 1997. PMID: 9066711.
4. Paul D, Qazilbash MH, Song K, Xu H, Sinha BK, Liu J, Cowan KH. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther 7:308-15, 2/2000. PMID: 10770641.
5. Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Auber M, Weisenborn R, Bunner P, Ericson SG. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model. Acta Haematol 110:173-8, 2003. PMID: 14663160.
6. Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Weisenborn R, Bunner P, Ericson SG. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Acta Haematol 109:119-23, 2003. PMID: 12714820.
7. Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18:703-13, xi, 6/2004. PMID: 15271401.
8. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 80:43-5, 9/2005. PMID: 16138357.
9. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106:1084-9, 3/2006. PMID: 16456814.
10. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47:1360-4, 7/2006. PMID: 16923569.
11. Qazilbash MH, Ueno N , Hosing C , de Lima M , Cortes J , Massaro A , Rivera Z, Deavers M , Adachi JA, Champlin RE. Strongyloidiasis after Unrelated Non-myeloablative Allogeneic Stem Cell Transplantation. Bone Marrow Transplant 38(5):393-4, 2006. PMID: 16845427.
12. Qazilbash MH, Saliba, R., Hosing, C., de Lima, M., Couriel, D., Mendoza, F., Qureshi, S. R., Weber, D. M., Wang, M., Flosser, T., Kebriaei, P., Popat, U., Alousi, A. M., Champlin, R., Giralt, S. Autologous Stem Cell Transplantation is Safe and Feasible in Elderly Patients with Multiple Myeloma. Bone Marrow Transplant 39(5):279-83, 3/2007. e-Pub 1/2007. PMID: 17262062.
13. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 13(9):1066-72, 9/2007. e-Pub 7/2007. PMID: 17697969.
14. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biol Blood Marrow Transplant 14(12):1401-7, 12/2008. PMID: 19041063.
15. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 7/2009. PMID: 19539212.
16. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 3/2010. PMID: 19668237.
17. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 9/2009. PMID: 19660722.
18. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, de Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. Biol Blood Marrow Transplant 15(10):1265-70, 10/2009. e-Pub 8/2009. PMID: 19747634.
19. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 8/2010. e-Pub 2/2010. PMID: 20178853.
20. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 4/2011. e-Pub 6/2010. PMID: 20581887.
21. Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 85(7):502-4, 7/2010. PMID: 20575022.
22. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 3/2011. e-Pub 7/2010. PMID: 20674757.
23. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 12/2010. e-Pub 8/24/2010. PMID: 20735170.
24. Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 52(1):137-41, 1/2011. PMID: 20939697.
25. Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary Systemic Amyloid Light Chain Amyloidosis Decompensating After Filgrastim-Induced Mobilization and Stem-Cell Collection. J Clin Oncol 29(4):e79-80, 2/2011. e-Pub 11/2010. PMID: 21060030.
26. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth Through Eighth Decades of Life. Biol Blood Marrow Transplant. e-Pub 2/2011. PMID: 21338705.
27. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. e-Pub 3/2011. PMID: 21423123.
28. Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. e-Pub 5/2011. PMID: 21575005.
29. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma. e-Pub 7/2011. PMID: 21780997.
30. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant. e-Pub 7/2011. PMID: 21767516.
31. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-2515, 5/2012. e-Pub 9/2011. PMID: 21887685.
32. Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant 48(2):269-277, 2/2013. e-Pub 7/2012. PMID: 22773122.
33. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-1826, 12/2012. e-Pub 6/2012. PMID: 22750645.
34. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 19(3):344-356, 3/2013. e-Pub 8/2012. PMID: 22922522.
35. Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 4/14/2010. PMCID: PMC3262333.
36. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-220, 2/2013. e-Pub 9/2012. PMID: 22982533.
37. Poon LM, Bassett Jr R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-670, 3/2013. e-Pub 10/2012. PMID: 23085830.
38. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-417, 3/2013. e-Pub 11/2012. PMID: 23128322.
39. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/13/2012. PMID: 23234514.
40. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. e-Pub 1/18/2013. PMID: 23330820.
41. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. e-Pub 3/2013. PMID: 23503529.
42. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Biol Blood Marrow Transplant. e-Pub 3/15/2013. PMID: 23507470.
43. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 5/2013. PMID: 23627452.
44. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant. e-Pub 4/30/2013. PMID: 23644077.
45. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma; relevance of p53 and its clinical implications. Exp Hematol. e-Pub 5/3/2013. PMID: 23648290.
46. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant. e-Pub 5/2013. PMID: 23733001.
47. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. e-Pub 6/8/2013. PMID: 23749720.
48. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 6/12/2013. PMID: 23769669.
49. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash M. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant. e-Pub 7/17/2013. PMID: 23872222.
50. Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics. e-Pub 8/19/2013. PMID: 23957592.

Abstracts

1. Uday R. Popat, Roland Bassett, Julianne Chen, Amin Majid Alousi, Paolo Anderlini, Stefan O. Ciurea, Chitra Hosing, Roy B. Jones, Partow Kebriaei, Issa F. Khouri, Sergej Konoplev, Marcos De Lima, Yago Nieto, Betul Oran, Muzaffar H. Qazilbash, Gabriela Rondon, Elizabeth J. Shpall, Srdan Verstovsek, Borje Andersson and Richard E. Champlin. Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. ournal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Volume 31(No 15):7011, 5/2013.
2. Antonio Martin Jimenez, Marcos De Lima, Uday R. Popat, Gautam Borthakur, Lynne Abruzzo, Borje Andersson, Guillermo Garcia-Manero, Elias Jabbour, Julianne Chen, Qaiser Bashir, Stefan O. Ciurea, Partow Kebriaei, Sairah Ahmed, Issa F. Khouri, Piyanuch Kongtim, Muzaffar H. Qazilbash, Gabriela Rondon, Elizabeth J. Shpall, Richard E. Champlin, and Betul Oran. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). Journal of Clinical Oncology- ASCO Annual Meeting Volume 31(No 15):7010, 5/2013.
3. Hans C. Lee, MD1, C. Cameron Yin, MD, PhD2, Muzaffar H. Qazilbash, MD3, Iris Wang, MD2*, Victoria Lu2* and Gary Lu, MD2*. Acquired Therapy-Related Cytogenetic Clones in Patients Treated for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
4. Zartash Gul, MD1*, Qaiser Bashir, MD2*, Yago Nieto, M.D., Ph.D.2, Nazeer Sherwani3*, Simrit Parmar, M.D.4, Nina Shah, MD4*, Yvonne T Dinh4*, Chitra M. Hosing, M.D.2,4, Uday R. Popat, M.D.2, Partow Kebriaei, M.D.2, Elizabeth J Shpall, MD2, Sergio A Giralt, MD5, Richard E. Champlin6 and Muzaffar H. Qazilbash, MD2. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
5. Amin M. Alousi, M.D.1, Rima M Saliba, PhD1*, Julianne Chen1*, Borje S Andersson, MD, PhD1*, Issa Khouri, MD2, Muzaffar H. Qazilbash, MD1, Uday R. Popat, M.D.1, Chitra M. Hosing, M.D.1, Stefan O. Ciurea1, Elizabeth J Shpall, MD1, Roy B. Jones, MD, Ph.D.1*, Partow Kebriaei, M.D.1, Yago Nieto, M.D., Ph.D.1, Paolo Anderlini, MD1, Marcos DeLima, MD3*, Gabriela Rondon4 and Richard E. Champlin1. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. ASH Annual Meeting 2012 Abstracts, 12/2012.
6. Zartash Gul, MD1, Hasan Khan2*, Qaiser Bashir, MD3, Nina Shah, MD4*, Simrit Parmar, M.D.5, Yvonne T Dinh6*, Chitra M. Hosing, M.D.3, Uday R. Popat, M.D.3, Partow Kebriaei, M.D.3, Paolo Anderlini, MD3, Elizabeth J Shpall, MD3, Sergio Giralt, MD7, Richard E. Champlin3 and Muzaffar H. Qazilbash, MD8. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
7. Dilshad Khan, MBBS1*, Krina Patel, MD2*, Sheeba K. Thomas, MD3, Donna M. Weber, M.D.3, Kay B Delasalle, B.S.4*, Chitra M. Hosing, M.D.5, Uday R. Popat, M.D.1, Qaiser Bashir, MD1*, Nina Shah, MD1*, Simrit Parmar, M.D.6, Richard E. Champlin5 and Muzaffar Qazilbash, M.D.5. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom’s Macroglobulinemia. ASH Annual Meeting 2012 Abstracts, 12/2012.
8. Jatin J. Shah, M.D.1, Robert Z. Orlowski, M.D., Ph.D.2, Sheeba K. Thomas, MD1, Raymond Alexanian, M.D.2, Michael Wang, M.D.3, Muzaffar H. Qazilbash, MD4, Uday R. Popat, M.D.5, Simrit Parmar, M.D.6, Nina Shah, MD7*, Qaiser Bashir7, Richard E. Champlin8 and Donna M. Weber, M.D.1. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
9. Jatin J. Shah, M.D.1, Donna M. Weber, M.D.1, Sheeba K. Thomas, MD1, Raymond Alexanian, M.D.2, Michael Wang, M.D.3, Muzaffar H. Qazilbash, MD4, Simrit Parmar, M.D.5, Nina Shah, MD6*, Qaiser Bashir, MD7, Uday R. Popat, M.D.8, Brandi Hilder9* and Robert Z. Orlowski, M.D., Ph.D.2. hase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
10. Simrit Parmar, M.D.1, Joshua Howell, PharmD2*, Michael Wang, M.D.3, Mubeen A Khan4,5*, Qaiser Bashir, MD2,4*, Jatin J. Shah, M.D.6, Nina Shah, MD2*, Uday R. Popat, M.D.7, Sergio A Giralt, MD8, Robert Z. Orlowski, M.D., Ph.D.9 and Muzaffar Qazilbash, M.D.4. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. ASH Annual Meeting 2012 Abstracts, 12/2012.
11. Amir Hamdi, M.D.*, LM Poon, M.D.*, Rima M. Saliba, Ph.D.*, Gabriela Rondon, M.D., Celina Ledesma*, Muzaffar Qazilbash, M.D., Chitra M. Hosing, M.D., Roy B. Jones, MD, Ph.D.*, Uday R. Popat, M.D., Yago Nieto, M.D., Ph.D., Amin M. Alousi, M.D., Stefan O. Ciurea, Elizabeth J. Shpall, M.D., Richard E. Champlin and Partow Kebriaei, M.D. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASH Annual Meeting 2012 Abstracts, 12/2012.
12. atin J. Shah, M.D.1, Sheeba K. Thomas, MD1, Donna M. Weber, M.D.1, Michael Wang, M.D.2, Raymond Alexanian, M.D.3, Muzaffar H. Qazilbash, MD4, Qaiser Bashir, MD5, Simrit Parmar, M.D.6, Nina Shah, MD7*, Uday R. Popat, M.D.5 and Robert Z. Orlowski, M.D., Ph.D.3. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
13. Krina Patel, MD1*, Robert Z. Orlowski, M.D., Ph.D.2, Nina Shah, MD3*, Qaiser Bashir3, Simrit Parmar, M.D.3, Yvonne T Dinh3*, Gabriela Rondon, MD3*, Sergio A Giralt, MD4, Richard E. Champlin3 and Muzaffar Qazilbash, M.D.3. Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
14. airah Ahmed, MD1, Rima M Saliba, Ph.D1*, Marcos De Lima, MD1, Gabriela Rondon, MD1, Partow Kebriaei, MD1, Tobi DeAnn Fisher, MPAS1*, Elias Jabbour, MD2, Julianne Chen1*, Hagop Kantarjian, MD2, Paolo Anderlini, MD1, Amin M Alousi, MD1, Chitra M Hosing, MD1, Borje Andersson, MD, PhD1, Roy B. Jones, MD, Ph.D.1*, Muzaffar H. Qazilbash, MD1, Elizabeth J. Shpall, MD1, Sergio Giralt, MD3 and Richard E Champlin, MD1. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. ASH Annual Meeting 2012 Abstracts, 12/2012.
15. Hosing C, Saliba R, Singh L, Popat U, Qazilbash M, Anderlini P, Nieto Y, Alousi A, Frazier E, Dabaja E, Champlin R, Duvic M. Total Skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sézary syndrome. Nature/2012 EBMT Abstract Book 47(Supplement 1):S85 (#O368), 4/2012.

Book Chapters

1. Qazilbash MH. Peptide Vaccines for AML. In: Immunotherapy and Gene Therapy. Springer Science. In Press.
2. Qazilbash MH, Giralt SA. Hematopoietic Cell Transplantation for Multiple Myeloma. In: Thomas' Hematopoietic Cell Transplantation, 4. Ed(s) Applebaum FR, Forman SJ, Negrin RS, Blume KG. Wiley Blackwell, 845-59, 2009. ISBN: 9781405153485.
3. Qazilbash MH, Cortes JE. Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology, Second. Ed(s) Abraham J, Gulley JL, Allegra C. Lippincott Williams & Wilkins: Baltimore, 331, 2005. ISBN: 0787-5116-0.
4. Qazilbash M. Chronic Leukemias. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 2004.
5. Qazilbash M. Chronic Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 2004.

Last updated: 11/15/2013